An assessment of implications of adaptive licensing for pharmaceutical intellectual property and regulatory exclusivity rights in the European Union.
One of the key advantages of adaptive licensing is to align the licensing of new medicines more closely with patient needs for earlier access to beneficial treatments. From an innovators perspective ‘earlier’ market access may seem an obvious incentive to gain earlier revenue generation. This is how...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2016
|